Vitamin A and its precursor (beta carotene) and synthetic analogs (retinoids) play an important role in the modulation of the growth and differentiation of normal, premalignant, and malignant cells in vivo and in culture. Vitamin A deficiency leads to squamous metaplasia, which can be reversed by vitamin A and by certain retinoids. Interestingly, the metaplasia that develops during vitamin A deficiency is similar to premalignant lesions caused by chemical carcinogens. Dysplastic leukoplakia and erythroplakia are uniquely measurable premalignant lesions that may progress in severity and ultimately result in frank malignancy. We recently completed a controlled, double-blind randomized trial of 13-cis retinoic acid versus placebo in oral leukoplakia. We detected and reported major but reversible activity of 13-cis retinoic acid against oral leukoplakia. Thus, our study strongly indicates that prolonged treatment with 13-cis retinoic acid at a tolerable dose may be necessary to maintain therapeutic effect. We therefore propose a clinical study using an intermediate dose of 13-cis retinoic acid as initial treatment followed by randomization to either low-dose 13-cis retinoic acid as a maintenance treatment or beta carotene as an alternative treatment. We now see more than 50 new patients annually in our institution and will have an additional 30 patients referred from the Dental School. This population will provide invaluable resources for combined clinical and laboratory investigations. During this study we will evaluate the levels of differentiation markers (cholesterol sulfate, involucrin, and transglutaminase) in tissue as biochemical intermediate endpoints and will measure micronuclei reduction as a biological marker, and we will attempt to correlate these markers to treatment. The information we obtain from this study will allow us to develop more rational regimens for the treatment of oral premalignant lesions and to establish a firm approach to chemoprevention of squamous cell carcinoma of the head and neck.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA046303-02
Application #
3549029
Study Section
(SRC)
Project Start
1987-09-30
Project End
1990-08-31
Budget Start
1988-09-01
Budget End
1989-08-31
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Hospitals
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Lippman, S M; Benner, S E; Hong, W K (1994) Retinoid chemoprevention studies in upper aerodigestive tract and lung carcinogenesis. Cancer Res 54:2025s-2028s
Benner, S E; Lippman, S M; Wargovich, M J et al. (1994) Micronuclei, a biomarker for chemoprevention trials: results of a randomized study in oral pre-malignancy. Int J Cancer 59:457-9
Hong, W K; Lippman, S M; Wolf, G T (1993) Recent advances in head and neck cancer--larynx preservation and cancer chemoprevention: the Seventeenth Annual Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 53:5113-20
Shin, D M; Chiao, P J; Sacks, P G et al. (1993) Activation of ribosomal protein S2 gene expression in a hamster model of chemically induced oral carcinogenesis. Carcinogenesis 14:163-6
Lee, J S; Kim, S Y; Hong, W K et al. (1993) Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion. J Natl Cancer Inst 85:1951-4
Lippman, S M; Batsakis, J G; Toth, B B et al. (1993) Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328:15-20
Chiao, P J; Shin, D M; Sacks, P G et al. (1992) Elevated expression of the ribosomal protein S2 gene in human tumors. Mol Carcinog 5:219-31
Lee, J S; Lippman, S M; Hong, W K et al. (1992) Determination of biomarkers for intermediate end points in chemoprevention trials. Cancer Res 52:2707s-2710s
Kim, J S; Steck, P A; Gallick, G E et al. (1992) Suppression by retinoic acid of epidermal growth factor receptor autophosphorylation and glycosylation in cultured human head and neck squamous carcinoma cells. J Natl Cancer Inst Monogr :101-10
Shin, D M; Kramer, A M; Dimery, I W et al. (1991) Phase II clinical trial of 4'-O-tetrahydropyranyl-adriamycin (THP-adriamycin) in recurrent squamous cell carcinoma of the head and neck. Invest New Drugs 9:89-91

Showing the most recent 10 out of 19 publications